For participants who receive therapeutic anticoagulation: stable anticoagulant regimen
Not currently receiving anticoagulation therapy
Need for anticoagulation
Concomitant anticoagulation at therapeutic doses with oral anticoagulants or platelet inhibitors
Current use of anticoagulation therapy
INR ? . (unless receiving anticoagulation therapy).
Subjects receiving anticoagulation therapy
concomitant use of therapeutic anticoagulation
Treatment with anticoagulation or antiplatelet agents, except for aspirin dosages of ? mg per day, within the last  weeks
For participants receiving therapeutic anticoagulation: stable anticoagulant regimen and stable INR during the  days immediately preceding initiation of study treatment
Requirement for chronic anticoagulation
On anticoagulation and unable to discontinue temporarily
Requires therapeutic doses of anticoagulants unless anticoagulation can be safely discontinued before surgery per standard practice (e.g. first deep vein thrombosis [DVT] for which anticoagulation has been at least  months and repeat imaging demonstrates resolution of DVT) or an inferior vena cava (IVC) filter can be used in place of anticoagulation; subjects are permitted to resume anticoagulation following surgery per discretion of treating physician and/or site standard operating procedures (SOPs)
Require therapeutic use of anticoagulation medications
History or evidence of thrombotic disorders within  months before first study treatment unless stable on anticoagulation for >  months
Patients on therapeutic or prophylactic anticoagulation will be excluded from enrollment on the protocol; however, patients can remain on the study if they develop a thrombosis that requires therapeutic anticoagulation during the course of protocol therapy
Subject is actively on anticoagulation therapy.
Subjects receiving anticoagulation therapy
Patient has a bleeding disorder or a screening platelet count </L, or requires continuous anticoagulation or bridging anticoagulation during the procedure
Patients on prophylactic or full-dose anticoagulation are eligible, provided the treating physician believes it is safe to temporarily withhold anticoagulation
FOR ALL PHASES (Ib AND II): Participants receiving anticoagulation therapy are not allowed
Requires use of therapeutic anticoagulation prior to registration\r\n* NOTE: thromboprophylaxis with any agent is permitted
Patients judged by their urologist or preoperative evaluation center (PEC) center to be unsafe to forgo pharmacologic prophylaxis or systemic anticoagulation postoperatively (whether or not they are on systematic anticoagulation for indications other than VTE)
Contraindication to biopsy or prostatectomy (for neoadjuvant cohort only):\r\n* Bleeding disorders\r\n* Artificial heart valve\r\n* Prothrombin time (PT)/partial thromboplastin time (PTT) >= . x ULN in patients not taking anticoagulation; patients on anticoagulation (e.g. enoxaparin, oral anticoagulants) are eligible regardless of PT/PTT; prior to biopsy, anticoagulation will be held per standard practice
anticoagulation with inability to stop anticoagulants prior to surgery
Is on anticoagulation that cannot be discontinued in the perioperative stage
Requirement for anticoagulation treatment that increases INR or aPTT above the normal range (low dose DVT or line prophylaxis is allowed).
Patients on anticoagulation therapy which cannot be held for metastatic biopsies
Abnormalities in coagulation such as bleeding diathesis, or treatment with anticoagulants (that cannot be safely held for biopsy) that would preclude tumor and skin biopsies\r\n* For fulvestrant: ongoing anticoagulation that would preclude an IM injection\r\n* For tamoxifen: documented hypercoagulable state not receiving anticoagulation
Unable or unwilling to take any prophylaxis; patients with history of or new/active deep vein thrombosis/embolism/thrombophilia are allowed to participate if they are on appropriate therapeutic anticoagulation during the treatment on the trial; these patients would not need the aspirin with the lenalidomide unless clinically indicated; therefore, patients must be able and willing to receive anticoagulation (prophylaxis versus therapeutic as clinically indicated)
Patients receiving anticoagulation therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulation
Patients on therapeutic anticoagulation; Note: prophylactic anticoagulation (i.e. intraluminal heparin) for venous or arterial access devices is allowed
Need for ongoing therapeutic anticoagulation
Subject is receiving anticoagulation; washout period of  days
ORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Chronic anticoagulation, not including aspirin, but including heparins, warfarin, oral anticoagulation or other platelet function inhibitors
HPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Chronic anticoagulation, not including aspirin, but including heparins, warfarin, oral anticoagulation or other platelet function inhibitors
Patients receiving therapeutic non-Coumadin anticoagulation are eligible, provided they are on a stable dose (per investigator judgment) of anticoagulant
Patients on therapeutic anticoagulation
Patients requiring therapeutic anticoagulation with drugs requiring INR monitoring or anti-platelet therapy, except for acetylsalicylic acid (aspirin) ?  mg per day, are not eligible
Patients requiring therapeutic anticoagulation and irreversible platelet inhibitors (e.g. clopidogrel, prasugrel, or ticagrelor). Low dose aspirin for cardiac prophylaxis is allowed.
Current use of anticoagulation; NOTE: use of low-dose anticoagulation medications (such as heparin) that are used to maintain the patency of a central intravenous catheter is allowed
Patients with TE event occurring >  months prior to enrollment and receiving active anticoagulation
Patients requiring therapeutic anticoagulation
Patients on therapeutic anticoagulation Note: prophylactic anticoagulation (i.e. intraluminal heparin) for venous or arterial access devices is allowed
Patients must not be on any anticoagulation
Therapeutic anticoagulation is not contraindicated, but for those patients on therapeutic anticoagulation, alteration in coagulation parameters is expected following initiation of dasatinib; for patients on therapeutic anticoagulation, coagulation parameters should be assessed weekly for the first cycle following initiation of dasatinib, weekly for the first cycle following a dose reduction, and weekly for a minimum of two weeks after stopping dasatinib
Anticoagulation with Lovenox (enoxaparin) is permitted, however, patients on anticoagulation with warfarin are not permitted on this study
Require therapeutic anticoagulation treatment, especially with Coumadin
Concomitant anticoagulation, at therapeutic doses, with anticoagulants.
Patients on oral anticoagulation therapy
Patients receiving anticoagulation therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulation
In the absence of therapeutic intent to anticoagulate the patient: INR > . or PT > . xULN or aPTT > . xULN Therapeutic anticoagulation.
For patients receiving therapeutic anticoagulation: stable anticoagulant regimen
Chronic anticoagulation, not including aspirin, but including heparins, warfarin, oral anticoagulation or other platelet function inhibitors, that can not, in the documented opinion of the investigator, safely be interrupted from at least  days prior to the initiation of the study regimen until after surgical resection of the tumor.
Concurrent treatment with anticoagulation medication, unless approved by Sponsor
Patients using oral or parenteral anticoagulation are not excluded provided they are on a stable dose of anticoagulant
Therapeutic-dose anticoagulation must be discontinued and coagulation parameters must be normalized prior to the first dose of GSK and fulvestrant.
Subject undergoing cardiothoracic surgery with anticoagulation must have anticoagulation reversed prior to target bleeding site (TBS) identification and treatment;
Patients must not be receiving therapeutic anticoagulation
Patients requiring anticoagulation or with uncontrolled bleeding are excluded
Those who require therapeutic anticoagulation with coumarin-derivative anticoagulants
Patients on active therapeutic anticoagulation
Anticoagulation is permitted but patients may only be on lovenox for this purpose.
Known coagulopathies, and those who require therapeutic anticoagulation with coumarin-derivative anticoagulants
Active bleeding tendency; NOTE: patients on therapeutic anticoagulation should be monitored carefully to maintain therapeutic level of anticoagulation to avoid increased risk of bleeding due to concurrent drug induced thrombocytopenia; it is suggested that patients who require anticoagulation therapy while on therapy use low molecular weight heparin (LMWH)
Concomitant anticoagulation with oral anticoagulants.
Prothrombin time or INR =< . x ULN unless receiving therapeutic anticoagulation
Patients on chronic anticoagulation such as Aspirin, Plavix, or Coumadin who cannot have anticoagulation held for procedures are not eligible
If on anticoagulation, participant must be on stable therapeutic dose prior to enrollment
Coagulopathy or anticoagulation therapy that cannot be safely corrected or interrupted for tumor biopsy
Current use of therapeutic anticoagulation therapy
Evidence of bleeding diathesis or coagulopathy; patients that are on anticoagulation therapy for deep vein thrombosis (DVT) will be allowed to enroll and continue on the treatment dose of enoxaparin or other anticoagulation such a warfarin
Patients must not be on any anticoagulation
Able to take required prophylactic anticoagulation.
Institutional normalized ratio (INR) =< . x ULN (this applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose)
Activated partial thromboplastin time (aPTT) =< . x ULN (this applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose)
Active therapeutic anticoagulation
Is receiving prophylactic or therapeutic anticoagulation with warfarin or any other oral anticoagulant
Therapeutic anticoagulation
Patients on fibrinolysis, full-dose therapeutic anticoagulation, or high dose antiplatelet therapy
Continuous anticoagulation therapy; patients who were on anticoagulant therapy must complete a washout period of at least  days and have confirmed normal coagulation parameters before study inclusion
Patient receiving anticoagulation
Use of therapeutic anticoagulation within  days of surgery (not including venous thromboembolism prophylaxis)
Active or recent (within prior  months) thrombus, irrespective of anticoagulation status
Documented venous thromboembolism while on therapeutic anticoagulation (anticoagulation failure)
Currently receiving anticoagulation treatment
Current oral steroid use or receiving daily therapeutic anticoagulation (e.g. Coumadin, Lovenox)
Documented venous thromboembolism while on therapeutic anticoagulation (anticoagulation failure)
Require chronic anticoagulation or anti-platelet therapy
Women on anticoagulation
Protein C deficiency (increased risk of skin necrosis do those on injectable anticoagulation)
For patients receiving therapeutic anticoagulation: stable anticoagulant regimen
Require chronic anticoagulation or anti-platelet therapy
a condition requiring prolonged anticoagulation or anti-platelets
Subjects on anticoagulation (other than aspirin) whom cannot have their anticoagulation held for the procedure due to other clinical reasons (i.e. recent cardiac stent placement)
Subjects on anticoagulation (other than aspirin) whom cannot have their anticoagulation held for the procedure due to other clinical reasons (i.e. recent cardiac stent placement)
Patients who require anticoagulation for whom biopsy would be contraindicated.
Active therapeutic anticoagulation
Patient receiving therapeutic anticoagulation
Subjects requiring anticoagulation not eligible
Require therapeutic use of anticoagulation medications